Lisa Delfini - May 22, 2024 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Signature
/s/ Christopher Galletta, attorney-in-fact
Stock symbol
TRVI
Transactions as of
May 22, 2024
Transactions value $
-$3,287
Form type
4
Date filed
5/24/2024, 04:12 PM
Previous filing
Feb 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRVI Common Stock Options Exercise $8.2K +16K +38.58% $0.51 57.6K May 22, 2024 Direct F1
transaction TRVI Common Stock Sale -$11.5K -4.35K -7.55% $2.64 53.3K May 22, 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Options Exercise $0 -16K -25% $0.00 48.1K May 22, 2024 Common Stock 16K $0.51 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 5,685 shares purchased through the Issuer's employee stock purchase plan.
F2 This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on May 22, 2024.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.64 to $2.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.